Phase II study of sorafenib in patients with relapsed or refractory lymphoma

British Journal of Haematology, 05/14/2012

Compared with patients with progressive disease (PD), responsive patients had significantly higher baseline levels of extracellular signal–regulated kinase phosphorylation and autophagy and presented a significant reduction of these parameters after 1 month of therapy. Sorafenib was well tolerated and had a clinical activity that warrants development of combination regimens.

Print Article Summary Cat 2 CME Report